HOME > OUR WORLD > RESEARCH & DEVELOPMENT > INTELLECTUAL PROPERTY MANAGEMENT

INTELLECTUAL PROPERTY MANAGEMENT GROUP (IPMG)

Lupin’s IPMG has been responsible for creating, cultivating, leveraging and securing an ever growing portfolio of high-value patents, product and research pipeline. Its IPMG has been carrying out patent litigations and challenges successfully.

The Company was first-to-file with respect to the generic versions of Belviq® tablets, Myrbetriq® extended release tablets and Eliquis® tablets. Lupin’s confirmed first-to-file products tally of 45 remains impressive. We successfully launched the generic versions of the following products with first-to-file exclusivity - Minastrin® 24 Fe (Ethinyl Estradiol; Norethindrone acetate, 0.02mg; 1mg, Chewable Tablets), Quartette® (Ethinyl Estradiol; Levonorgestrel, 0.02mg, 0.15mg; 0.025mg, 0.15mg; 0.03mg, 0.15mg; 0.01mg, N/A, Tablets) and Pristiq® (Desvenlafaxine 50mg and 100mg ER Tablets).

In addition, the Company settled twelve pending patent litigations during the fiscal and received favorable decisions on Axiron®, Effient® and Abilify®.

In FY 2017, our research led patent filing grew strong as we filed for 312 applications. Since its inception, Lupin has filed 2,837 patents across a wide global network. The patent applications filed during FY 2017 includes 39 formulation patent applications, 128 API/process patent applications in addition to 42 biotech patent applications and 103 NDDD patent applications. We successfully secured 72 patents including 3 formulation patents, 3 API patents and 66 NDDD patents.